Breast Cancer Now media statements
We respond to research about radiotherapy and long-term breast cancer survival
Dr Kotryna Temcinaite, our Senior Research Communications Manager, has responded to research presented at the 13th European Breast Cancer Co...
We respond to research about women with benign breast disease being at higher risk of breast cancer in the long term
Dr Kotryna Temcinaite, our Senior Research Communications Manager, has commented on research presented at the 13th European Breast Cancer Co...
We respond to latest NHSE Cancer Wait Times data
Melanie Sturtevant, Associate Director for Policy, Evidence and Influencing at Breast Cancer Now, has commented on the latest NHS England Ca...
We respond to NICE’s devastating decision to provisionally reject the use of olaparib on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said NICE’s decision to provisionally reject the use of olaparib on the NHS wa...
We respond to the launch of the first UK proton beam therapy trial for breast cancer patients
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
We respond to new estimates that 57,215 people were living with secondary (metastatic) breast cancer in England in 2020 to 2021
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, has commented on the new estimates.
We respond to NICE’s approval of trastuzumab deruxtecan (Enhertu) for use on the Cancer Drugs Fund
Chief Executive of Breast Cancer Now, Baroness Delyth Morgan, has commented on NICE'S decision to approve trastuzumab deruxtecan for use on ...
We respond to double SMC drug announcement - adjuvant abemaciclib and alpelisib with fulvestrant
Chief Executive of Breast Cancer Now, Baroness Delyth Morgan, has commented on the double announcement by the Scottish Medicines Consortium.
Pembrolizumab in combination with chemo is approved for use on the NHS in Scotland
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to research about a potential new treatment for advanced breast cancer patients
Dr Kotryna Temcinaite, senior research communications manager at Breast Cancer Now, said: